Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score

Detalhes bibliográficos
Autor(a) principal: Hering,Flávio Luiz Ortiz
Data de Publicação: 2001
Outros Autores: Lipay,Mônica Vannucci Nunes, Lipay,Marco Aurélio Silva, Rodrigues,Paulo Roberto Teixeira, Nesralah,Luciano José, Srougi,Miguel
Tipo de documento: Artigo
Idioma: eng
Título da fonte: São Paulo medical journal (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802001000400005
Resumo: CONTEXT: Multiple genetic and epigenetic factors have been implicated in the oncogenesis and progression of prostate cancer. The major difficulty is in that the clinical management stems from the reality that reliable and accurate prognostic biomarkers are not available and that effective treatment regimens forming hormone-resistant prostate cancers are yet to be developed. Among the most important regulators of apoptosis and programmed cell death is the bcl-2 gene and its related proteins. Elevated levels of bcl-2 protein may contribute to the progression of prostate cancers to a metastatic and hormone-insensitive state characterized by poor responses to chemotherapy. OBJECTIVE: To characterize the expression of bcl-2 proteins as a prognostic factor in humans. DESIGN: A retrospective approach. SETTING: Urology section, Federal University of São Paulo. DIAGNOSTIC TEST USED: Immunohistochemical analysis using bcl-2 protein antibody and normal staining by hematoxylin-eosin. MAIN MEASUREMENTS: Prognostic relations and protein expression were evaluated considering the total sample (28) divided into two groups, high (8 to 10) and low (2 to 4), separated according to the histological differentiation grade (Gleason score) with 10 and 18 samples, respectively. RESULTS: The differentiation of grade into two groups separated according to the Gleason score in low and high types presented different bcl-2 expression (P < 0.001). CONCLUSION: The higher frequency of bcl-2 immunostaining in tumor samples was observed in association with more advanced Gleason scores and suggests that an increase in the ratio of this anti-apoptotic protein often occurs during progression of prostate cancers.
id APM-1_36a4151cfd971e3a2f9a954a43ce53ef
oai_identifier_str oai:scielo:S1516-31802001000400005
network_acronym_str APM-1
network_name_str São Paulo medical journal (Online)
repository_id_str
spelling Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason scorebcl-2ProstateProstate adenocarcinomaApoptosisCONTEXT: Multiple genetic and epigenetic factors have been implicated in the oncogenesis and progression of prostate cancer. The major difficulty is in that the clinical management stems from the reality that reliable and accurate prognostic biomarkers are not available and that effective treatment regimens forming hormone-resistant prostate cancers are yet to be developed. Among the most important regulators of apoptosis and programmed cell death is the bcl-2 gene and its related proteins. Elevated levels of bcl-2 protein may contribute to the progression of prostate cancers to a metastatic and hormone-insensitive state characterized by poor responses to chemotherapy. OBJECTIVE: To characterize the expression of bcl-2 proteins as a prognostic factor in humans. DESIGN: A retrospective approach. SETTING: Urology section, Federal University of São Paulo. DIAGNOSTIC TEST USED: Immunohistochemical analysis using bcl-2 protein antibody and normal staining by hematoxylin-eosin. MAIN MEASUREMENTS: Prognostic relations and protein expression were evaluated considering the total sample (28) divided into two groups, high (8 to 10) and low (2 to 4), separated according to the histological differentiation grade (Gleason score) with 10 and 18 samples, respectively. RESULTS: The differentiation of grade into two groups separated according to the Gleason score in low and high types presented different bcl-2 expression (P < 0.001). CONCLUSION: The higher frequency of bcl-2 immunostaining in tumor samples was observed in association with more advanced Gleason scores and suggests that an increase in the ratio of this anti-apoptotic protein often occurs during progression of prostate cancers.Associação Paulista de Medicina - APM2001-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802001000400005Sao Paulo Medical Journal v.119 n.4 2001reponame:São Paulo medical journal (Online)instname:Associação Paulista de Medicinainstacron:APM10.1590/S1516-31802001000400005info:eu-repo/semantics/openAccessHering,Flávio Luiz OrtizLipay,Mônica Vannucci NunesLipay,Marco Aurélio SilvaRodrigues,Paulo Roberto TeixeiraNesralah,Luciano JoséSrougi,Migueleng2001-08-03T00:00:00Zoai:scielo:S1516-31802001000400005Revistahttp://www.scielo.br/spmjhttps://old.scielo.br/oai/scielo-oai.phprevistas@apm.org.br1806-94601516-3180opendoar:2001-08-03T00:00São Paulo medical journal (Online) - Associação Paulista de Medicinafalse
dc.title.none.fl_str_mv Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
title Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
spellingShingle Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
Hering,Flávio Luiz Ortiz
bcl-2
Prostate
Prostate adenocarcinoma
Apoptosis
title_short Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
title_full Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
title_fullStr Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
title_full_unstemmed Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
title_sort Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score
author Hering,Flávio Luiz Ortiz
author_facet Hering,Flávio Luiz Ortiz
Lipay,Mônica Vannucci Nunes
Lipay,Marco Aurélio Silva
Rodrigues,Paulo Roberto Teixeira
Nesralah,Luciano José
Srougi,Miguel
author_role author
author2 Lipay,Mônica Vannucci Nunes
Lipay,Marco Aurélio Silva
Rodrigues,Paulo Roberto Teixeira
Nesralah,Luciano José
Srougi,Miguel
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Hering,Flávio Luiz Ortiz
Lipay,Mônica Vannucci Nunes
Lipay,Marco Aurélio Silva
Rodrigues,Paulo Roberto Teixeira
Nesralah,Luciano José
Srougi,Miguel
dc.subject.por.fl_str_mv bcl-2
Prostate
Prostate adenocarcinoma
Apoptosis
topic bcl-2
Prostate
Prostate adenocarcinoma
Apoptosis
description CONTEXT: Multiple genetic and epigenetic factors have been implicated in the oncogenesis and progression of prostate cancer. The major difficulty is in that the clinical management stems from the reality that reliable and accurate prognostic biomarkers are not available and that effective treatment regimens forming hormone-resistant prostate cancers are yet to be developed. Among the most important regulators of apoptosis and programmed cell death is the bcl-2 gene and its related proteins. Elevated levels of bcl-2 protein may contribute to the progression of prostate cancers to a metastatic and hormone-insensitive state characterized by poor responses to chemotherapy. OBJECTIVE: To characterize the expression of bcl-2 proteins as a prognostic factor in humans. DESIGN: A retrospective approach. SETTING: Urology section, Federal University of São Paulo. DIAGNOSTIC TEST USED: Immunohistochemical analysis using bcl-2 protein antibody and normal staining by hematoxylin-eosin. MAIN MEASUREMENTS: Prognostic relations and protein expression were evaluated considering the total sample (28) divided into two groups, high (8 to 10) and low (2 to 4), separated according to the histological differentiation grade (Gleason score) with 10 and 18 samples, respectively. RESULTS: The differentiation of grade into two groups separated according to the Gleason score in low and high types presented different bcl-2 expression (P < 0.001). CONCLUSION: The higher frequency of bcl-2 immunostaining in tumor samples was observed in association with more advanced Gleason scores and suggests that an increase in the ratio of this anti-apoptotic protein often occurs during progression of prostate cancers.
publishDate 2001
dc.date.none.fl_str_mv 2001-07-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802001000400005
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802001000400005
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1516-31802001000400005
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Paulista de Medicina - APM
publisher.none.fl_str_mv Associação Paulista de Medicina - APM
dc.source.none.fl_str_mv Sao Paulo Medical Journal v.119 n.4 2001
reponame:São Paulo medical journal (Online)
instname:Associação Paulista de Medicina
instacron:APM
instname_str Associação Paulista de Medicina
instacron_str APM
institution APM
reponame_str São Paulo medical journal (Online)
collection São Paulo medical journal (Online)
repository.name.fl_str_mv São Paulo medical journal (Online) - Associação Paulista de Medicina
repository.mail.fl_str_mv revistas@apm.org.br
_version_ 1754209260384813056